SCHEMBL6543170

SCHEMBL6543170

CCOC(=O)c1ccc(N2CCNCC2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 4/20 0.42
HPGD P15428 2/20 0.42
ALDH1A1 P00352 6/20 0.41
HSP90AA1 P07900 2/20 0.41
MAPK1 P28482 2/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TSHR P16473 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ATM Q13315 1/20 0.38
FDFT1 P37268 1/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
ESR1 P03372 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27561229 0.81 SLC6A2 (0.44) ALDH1A1MAPK1TSHRGPR119
SCHEMBL15008622 0.81 ADRB1 (0.36) HPGDALDH1A1TSHRCA12CA1
SCHEMBL20141459 0.81 ADRB1 (0.36) HPGDALDH1A1TSHRCA12CA1
SCHEMBL19617168 0.80 HTT (0.49) HTTHPGDALDH1A1HSP90AA1MAPK1
SCHEMBL7519138 0.80 ALDH1A1 (0.34) ALDH1A1NPSR1SMN1; SMN2GPR119
SCHEMBL4429861 0.78 RAD52 (0.36) HPGDNPSR1GPR119
SCHEMBL4615210 0.78 GPR119 (0.36) GPR119
SCHEMBL5674603 0.78 MAPT (0.50) ALDH1A1MAPK1TDP1SMN1; SMN2
SCHEMBL7376264 0.77 LGMN (0.40) ALDH1A1
SCHEMBL5388810 0.77 ALDH1A1 (0.42) ALDH1A1TDP1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 HTT 4854/4885HPGD 4160/4885ALDH1A1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.